Acute Cutaneous Lupus Erythematosus (ACLE) Treatment & Management
- Author: Ivan D Camacho, MD; Chief Editor: William D James, MD more...
Systemic corticosteroids usually are the mainstay of therapy for systemic disease. Skin changes tend to respond in tandem with the systemic response to treatment. A rheumatologist usually undertakes systemic treatment.
Additional immunosuppressive agents, such as azathioprine, cyclophosphamide, and thalidomide, are used as adjuvant therapy to treat systemic disease because of steroid-sparing effects.[10, 11]
Hydroxychloroquine also has been shown to have steroid-sparing effects and is administered as first-line therapy to most patients with systemic disease. The effects of hydroxychloroquine on skin lesions are especially beneficial.
Intravenous IgG and rituximab have been used in controlling recalcitrant disease.[12, 13, 14, 15, 16]
Mycophenolate mofetil has shown poor results in disease refractory to multiple treatment modalities.
One case reports describes the effectiveness of plasmapheresis for refractory TEN-like acute cutaneous lupus erythematosus.
Topical tacrolimus 0.1% ointment has shown to provide at least temporary benefit, especially in acute, edematous, nonhyperkeratotic lesions of cutaneous lupus erythematosus, in a small multicenter, randomized, double-blind, vehicle-controlled trial.
Recently, Díez et al described the positive clinical, histopathologic, and immunohistolgic effect of pulsed dye laser on cutaneous lupus erythematosus lesions, with clinical improvement in 8 of 9 patients (88.9%), reduction of the dermal lymphocytic infiltrate, basal layer damage, mucin deposition, and intracellular adhesion molecule (ICAM) and vascular cell adhesion molecule (VCAM) expression.
Cutaneous lupus erythematosus lesions may be induced and exacerbated by ultraviolet radiation exposure, and patients with cutaneous manifestations of lupus erythematousus are generally considered photosensitive. Patients with acute cutaneous lupus erythematous require extensive education about avoidance of sun exposure, photoprotection through physical barriers such as protective clothing, and daily application of broad-spectrum sunscreens.
Diet and activity
Dietary restrictions may be necessary in the presence of renal compromise. In terms of activity, advise patients with acute cutaneous lupus erythematosus to avoid activities involving excessive exposure to the sun.
Refer patients with clinical and serologic evidence of lupus erythematosus to a rheumatologist for further treatment. Refer patients with red blood cell casts, significant proteinuria (>0.5 g/mL/24h), and a diastolic blood pressure of more than 90 mm Hg to a nephrologist.
Precautions in Corticosteroid Use
When administering systemic corticosteroids, address adverse effects such as diabetes mellitus, hypertension, osteonecrosis, the stigmata of Cushing syndrome, and the risk of osteoporosis.
Perform a baseline bone densitometry scan, and, if normal, repeat the scan at 6 months. If osteoporosis is present, refer the patient to an osteoporosis specialist for consideration of treatment with bisphosphonates.
Ideally, perform 24-hour urine collection to check calcium levels, since steroids enhance renal excretion of calcium, thereby increasing the patient's susceptibility to developing renal stones. If the results are normal, administer cholecalciferol (400-800 IU/d) and calcium (1500 mg/d). If evidence of hypercalciuria is present, administer thiazide diuretics until levels return to normal.
An investigational drug, belimumab, is currently undergoing phase III clinical trials for the potential treatment of systemic lupus erythematosus. It is a neutralizing B-lymphocyte stimulator monoclonal antibody that inhibits the biologic activity of the soluble form of essential B cells.
Doses used in the phase II trials were randomized to 1, 4, or 10 mg/kg intravenously on days 1, 14, and 28, and then every 28 days for 76 weeks. The treatment significantly improved the systemic lupus erythematosus disease activity index (SLEDAI) scores in seropositive patients (ANA ≥1:80 or anti-dsDNA >30 IU) and the physician global assessment score.
Epratuzumab is also investigational. It is a humanized anti-CD22 monoclonal antibody that partially depletes B cells. Treatment is shown to decrease disease activity but not autoantibody levels in patients with moderately active systemic lupus erythematosus.
In an open-label, single-case study of 14 patients with systemic lupus erythematosus, patients received intravenous epratuzumab at 360 mg/m2 every 2 weeks for 4 doses, with analgesic/antihistamine premedication prior to each dose. Total British Isle Lupus Assessment Group (BILAG) scores were decreased by greater than or equal to 50% in all 14 patients at 6 weeks.
Renner R, Sticherling M. The different faces of cutaneous lupus erythematosus. G Ital Dermatol Venereol. 2009 Apr. 144(2):135-47. [Medline].
Moghadam-Kia S, Chilek K, Gaines E, et al. Cross-sectional analysis of a collaborative Web-based database for lupus erythematosus-associated skin lesions: prospective enrollment of 114 patients. Arch Dermatol. 2009 Mar. 145(3):255-60. [Medline]. [Full Text].
Parodi A, Cozzani E. Cutaneous manifestations of lupus erythematosus. G Ital Dermatol Venereol. 2014 Oct. 149 (5):549-54. [Medline].
Torchia D, Romanelli P, Kerdel FA. Erythema multiforme and Stevens-Johnson syndrome/toxic epidermal necrolysis associated with lupus erythematosus. J Am Acad Dermatol. 2012. 67(3):417-21. [Medline].
Ziemer M, Kardaun SH, Liss Y, Mockenhaupt M. Stevens-Johnson syndrome and toxic epidermal necrolysis in patients with lupus erythematosus: a descriptive study of 17 cases from a national registry and review of the literature. Br J Dermatol. 2012. 166(3):575-600. [Medline].
Ting W, Stone MS, Racila D, Scofield RH, Sontheimer RD. Toxic epidermal necrolysis-like acute cutaneous lupus erythematosus and the spectrum of the acute syndrome of apoptotic pan-epidermolysis (ASAP): a case report, concept review and proposal for new classification of lupus erythematosus vesiculobullous skin lesions. Lupus. 2004. 13(12):941-50. [Medline].
Bielsa I, Guinovart RM, Fernández-Figueras MT, Rodríguez C, Ferrándiz C. Cutaneous lupus erythematosus on the elbows: a peculiar localization. 2012. 21(1):84-8. [Medline].
Jerdan MS, Hood AF, Moore GW, Callen JP. Histopathologic comparison of the subsets of lupus erythematosus. Arch Dermatol. 1990 Jan. 126(1):52-5. [Medline].
Böckle BC, Stanarevic G, Sepp NT. Detection of Ro/SS-A antibodies in lupus erythematosus: what does it mean for the dermatologist?. J Am Acad Dermatol. 2013 Mar. 68(3):385-94. [Medline].
Cortés-Hernández J, Torres-Salido M, Castro-Marrero J, Vilardell-Tarres M, Ordi-Ros J. Thalidomide in the treatment of refractory cutaneous lupus: prognostic factors of clinical outcome. Br J Dermatol. 2011 Oct 16. [Medline].
Raptopoulou A, Linardakis C, Sidiropoulos P, Kritikos HD, Boumpas DT. Pulse cyclophosphamide treatment for severe refractory cutaneous lupus erythematosus. Lupus. 2010. 19(6):744-7. [Medline].
Goodfield M, Davison K, Bowden K. Intravenous immunoglobulin (IVIg) for therapy-resistant cutaneous lupus erythematosus (LE). J Dermatolog Treat. 2004 Jan. 15(1):46-50. [Medline].
Kok MR, Vos K, Bos JD, Tak PP. Remission of incapacitating acute cutaneous lupus erythematosus in a patient with systemic lupus erythematosus by B cell-depletive therapy. J Clin Rheumatol. 2010 Oct. 16(7):345. [Medline].
Uthman I, Taher A, Abbas O, Menassa J, Ghosn S. Successful treatment of refractory skin manifestations of systemic lupus erythematosus with rituximab: report of a case. Dermatology. 2008. 216(3):257-9. [Medline].
Vital EM, Wittmann M, Edward S, Md Yusof MY, MacIver H, Pease CT, et al. Brief report: responses to rituximab suggest B cell-independent inflammation in cutaneous systemic lupus erythematosus. Arthritis Rheumatol. 2015 Jun. 67 (6):1586-91. [Medline].
Ky C, Swasdibutra B, Khademi S, Desai S, Laquer V, Grando SA. Efficacy of Intravenous Immunoglobulin Monotherapy in Patients with Cutaneous Lupus Erythematosus: Results of Proof-of-Concept Study. Dermatol Reports. 2015 Mar 16. 7 (1):5804. [Medline].
Pisoni CN, Obermoser G, Cuadrado MJ, et al. Skin manifestations of systemic lupus erythematosus refractory to multiple treatment modalities: poor results with mycophenolate mofetil. Clin Exp Rheumatol. 2005 May-Jun. 23(3):393-6. [Medline].
Simsek I, Cinar M, Erdem H, Pay S, Meric C, Dinc A. Efficacy of plasmapheresis in the treatment of refractory toxic epidermal necrolysis-like acute cutaneous lupus erythematosus. Lupus. 2008. 17(6):605-6. [Medline].
Kuhn A, Gensch K, Haust M, et al. Efficacy of tacrolimus 0.1% ointment in cutaneous lupus erythematosus: a multicenter, randomized, double-blind, vehicle-controlled trial. J Am Acad Dermatol. 2011 Jul. 65(1):54-64, 64.e1-2. [Medline].
Díez MT, Boixeda P, Moreno C, González JA, Zamorano ML, Olasolo PJ. Histopathology and immunohistochemistry of cutaneous lupus erythematosus after pulsed dye laser treatment. Dermatol Surg. 2011 Jul. 37(7):971-81. [Medline].
Kuhn A, Ruland V, Bonsmann G. Photosensitivity, phototesting, and photoprotection in cutaneous lupus erythematosus. Lupus. 2010 Aug. 19(9):1036-46. [Medline].
Ding C, Foote S, Jones G. B-cell-targeted therapy for systemic lupus erythematosus: an update. BioDrugs. 2008. 22(4):239-49. [Medline].